| [1] |
Harrison DG. The immune system in hypertension[J]. Trans Am Clin Climatol Assoc，2014，125：130-138.
|
| [2] |
Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events[J]. JAMA，2004，292(19)：2343-2349.
|
| [3] |
Heymans S. Inflammation and cardiac remodeling during viral myocarditis[J]. Ernst Schering Res Found Workshop，2006，55：197-218.
|
| [4] |
Sasamura H, Azegami T, Itoh H. Current status of vaccination therapy for hypertension[J]. Nihon Rinsho, 2012，70(9)：1627-1632.
|
| [5] |
Zeymer U, Dechend R, Deeg E, et al. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry[J]. Int J Clin Pract，2012，66(3)：251-261.
|
| [6] |
Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin Ⅱ[J]. Am J Physiol Regul Integr Comp Physiol，2009, 296(2)：R208-216.
|
| [7] |
Eckel RH, Wassef M, Chait A, et al. Prevention conference Ⅵ：diabetes and cardiovascular disease: Writing Group Ⅱ：pathogenesis of atherosclerosis in diabetes[J]. Circulation，2002，105(18)：e138-143.
|
| [8] |
Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future[J]. Circulation，1999，99(8)：1091-1100.
|
| [9] |
Dzielak DJ. The immune system and hypertension[J]. Hypertension，1992，19(1 Suppl)：136-144.
|
| [10] |
Rosskopf D, Hartung K, Hense J, et al. Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients[J]. Hypertension，1995，26(3)：432-435.
|
| [11] |
Harrison DG, Vinh A, Lob H, et al. Role of the adaptive immune system in hypertension[J]．Curr Opin Pharmacol，2010，10(2)：203-207.
|
| [12] |
Collett JA, Hart AK, Patterson E, et al. Renal angiotensin Ⅱ type 1 receptor expression and associated hypertension in rats with minimal SHR nuclear genome[J]. Physiol Rep，2013，1(5)：e00104.
|
| [13] |
Blagonravov ML, Frolov VA, Azova MM, et al. Characteristics of circadian rhythm of blood pressure during long-term hypertension development in SHR rats[J]. Bull Exp Biol Med，2013，155(5)：612-614.
|
| [14] |
Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury[J]. Hypertension，2003，42(1)：31-38.
|
| [15] |
Priyanka HP, Krishnan HC, Singh RV, et al. Estrogen modulates in vitro T cell responses in a concentration-and receptor-dependent manner: effects on intracellular molecular targets and antioxidant enzymes[J]. Mol Immunol，2013，56(4)：328-339.
|
| [16] |
Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach[J]. Cardiovasc Pathol，2004，13(3)：125-138.
|
| [17] |
Heymans S, Pauschinger M, De Palma A, et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis[J]. Circulation，2006，114(6)：565-573.
|
| [18] |
Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy[J]. Proc Natl Acad Sci USA，2000，97(23)：12746-12751.
|
| [19] |
Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling[J]. Circ Res，2004，94(9)：1203-1210.
|
| [20] |
Mendelsohn ME. Protective effects of estrogen on the cardiovascular system[J]. Am J Cardiol，2002，89(12A)：12E-17E；discussion 17E-18E.
|
| [21] |
Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system[J]. N Engl J Med，1999，340(23)：1801-1811.
|
| [22] |
Bourassa PA, Milos PM, Gaynor BJ, et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice[J]. Proc Natl Acad Sci USA，1996，93(19)：10022-10027.
|
| [23] |
Arnal JF, Gourdy P, Garmy-Susini B, et al. Usefulness of experimental models to understand the vascular effects of estrogens[J]. Med Sci (Paris)，2003，19(12)：1226-1232.
|
| [24] |
Arnal JF, Scarabin PY, Trémollières F, et al. Estrogens in vascular biology and disease: where do we stand today[J]? Curr Opin Lipidol，2007，18(5)：554-560.
|